pimodivir

Pimodivir is an orally bioavailable small molecule antiviral drug developed for the treatment of influenza A infection. It acts as a non-nucleoside inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A virus polymerase complex. By occupying the cap-binding domain of PB2, pimodivir blocks its interaction with the 7-methyl GTP (m7GTP) cap structure on host mRNA, thereby inhibiting the "cap-snatching" process essential for viral mRNA synthesis and subsequent replication. This mechanism disrupts early stages of viral transcription and reduces RNA replication in infected cells. Pimodivir was initially discovered by Vertex Pharmaceuticals and later developed by Janssen (a Johnson & Johnson company). Although it showed promising results in Phase II clinical trials, further development was discontinued due to lack of significant benefit over standard-of-care treatments[1][2][3][5][6][7][8].

Brand names

Pimodivir

Other names

1629869-44-8Pimodivir [USAN]